Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its product candidates include EBI-005, a novel interleukin-1 receptor antagonist that is in Phase III clinical program for the treatment of moderate to severe dry eye diseases; and has completed Phase II clinical trial for the treatment of allergic conjunctivitis. The company’s preclinical product candidates comprise EBI-031, a novel inhibitor of the cytokine interleukin-6 for the treatment of retinal dis...
215 First Street
Cambridge, MA 02142
Founded in 2008
Eleven Biotherapeutics Seeks Acquisitions
Mar 12 15
Eleven Biotherapeutics, Inc. (NasdaqGM:EBIO) has filed a Shelf Registration in the amount of $200.00 million, Eleven Biotherapeutics will use the net proceeds for research and development of our product pipeline, acquisition of companies or businesses, repayment and refinancing of debt, working capital and capital expenditures.
Eleven Biotherapeutics, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2014
Mar 4 15
Eleven Biotherapeutics, Inc. reported unaudited earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported collaboration revenue of $375,000 compared to $510,000 a year ago. Loss from operations was $7,095,000 compared to $4,120,000 a year ago. Net loss applicable to common stockholders was $8,139,000 or $0.49 per basic and diluted share compared to $6,208,000 or $4.29 per basic and diluted share a year ago.
For the year, the company reported collaboration revenue of $2,243,000 compared to $1,334,000 a year ago. Loss from operations was $32,931,000 compared to $16,478,000 a year ago. Net loss applicable to common stockholders was $34,675,000 or $2.37 per basic and diluted share compared to $21,882,000 or $16.18 per basic and diluted share a year ago.
Eleven Biotherapeutics, Inc. to Report Q4, 2014 Results on Mar 04, 2015
Feb 23 15
Eleven Biotherapeutics, Inc. announced that they will report Q4, 2014 results at 8:30 AM, US Eastern Standard Time on Mar 04, 2015